Print this page
A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Primary Objectives:
Part 1 (Dose Escalation)
To characterize the safety and tolerability of JNJ-95804306 and identify putative RP2D regimen(s) in R/R AML/HR MDS and R/R CLL/SLL in monotherapy and in combination(s)
Part 2 (Dose Expansion)
To further characterize the safety for JNJ-95804306 at the putative RP2D(s) in the expansion cohort(s) in monotherapy and in combination(s)
Secondary Objectives:
To assess PK of JNJ-95804306 in monotherapy and in combination(s)
To evaluate the preliminary anti-tumor clinical activity of JNJ-95804306 in R/R AML/HR MDS and R/R CLL/SLL in monotherapy and in combination(s)
Protocol Number:
022602
Phase:
Phase I
Applicable Disease Sites:
Leukemia, not otherwise specified
Leukemia, other
Leukemia, other
Principal Investigator:
Neil Palmisiano
Scope:
National
Participating Institutions:
- Rutgers University
For further information about clinical trials, please contact us at 732-235-7356.